Skip to content

Study · Not a test of the peptide alone · 2004

1 result

Basal and stimulated levels of growth hormone, insulin-like growth factor-I (IGF-I), IGF-I binding and IGF-binding proteins in beta-thalassemia major.

Karydis I, Karagiorga-Lagana M, Nounopoulos C, Tolis G

Journal of pediatric endocrinology & metabolism : JPEM1 Jan 2004Cited by 7 (Europe PMC)

PMID14960017 (opens in a new tab)DOI10.1515/jpem.2004.17.1.17 (opens in a new tab)PepBankPUB-14960017
Publisher pagePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone1

In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Hexarelin.

  1. 01HumanNot a test of Hexarelin aloneObservational studyActivity measurement

    In prepubertal patients with beta-thalassemia major, peak GH after a hexarelin stimulation test was higher in short-stature patients (group A) than in patients with normal stature (group B).

    In plain wordsIn children with beta-thalassemia major, short children had a higher growth hormone peak after hexarelin than children of normal height.

    Peptide
    Hexarelin
    Outcome
    IncreasePeak GH after Hexarelin stimulation
    Study

    n = 15

    Comparator
    Group B (normal stature)
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Measurements

    Peak GH
    27.9 ng/ml
    group A
    Peak GH
    9.1 ng/ml
    group B

    Source sentences

    Summary
    Peak GH levels after Hexarelin stimulation test were higher in group A (A: 27.9 +/- 15.6 ng/ml vs B: 9.1 +/- 4.7 ng/ml) (Wilcoxon test, p < 0.05).
    1 context sentence
    Summary · context
    Eight prepubertal patients with short stature (group A) and seven prepubertal patients with normal stature (group B) were studied.

    In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Hexarelin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.